Adverse effects: euphoric behaviour · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: euphoric behaviour compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
SoF9. Change in taste short-term (Quantitative Sensory Testing gustative threshold): single study narratively reported no difference in short-term gustation thresholds; 38 participants (1 RCT, topical urea); very low.
1 study · 38 participants
Very low
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in quality of life (QoL) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - anxiety (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - anxiety (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in taste compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
1 study · 37 participants
Very low
Adverse events: worsening of hypertension · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: increase in blood pressure compared with placebo (very low certainty).
1 finding from 1 review
Relief of pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in pain compared with placebo; GRADE not reported.
1 finding from 1 review
RR 4.29 [0.67, 27.24]
1 study
GRADE not reported
Effectiveness · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Mean VAS pain per day · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in mean VAS pain per day compared with placebo; GRADE not reported.
1 finding from 1 review
Days to resolution of pain / epithelialization; number of aphthae per month · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Pain score · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Vitamin B12 (sublingual, 1000 mcg daily for 6 months) led to lower pain score compared with placebo; GRADE not reported.
1 finding from 1 review